Trial Condition(s):
OREOT – Observational Retrospective pharmaco-Epidemiological French study On CKD in T2DM disease
21333
Not Available
Not Available
Not Available
L'objectif principal de cette étude est d'évaluer la prévalence et l'incidence des patients atteints de maladie rénale chronique et de diabète de type 2 dans la population française.
Les objectifs secondaires de l’étude sont :
• D’évaluer la prévalence et l'incidence de sous-populations d'intérêt chez les patients atteints de maladie rénale chronique et de diabète de type 2 ;
• De décrire chez les patients atteints de maladie rénale chronique et de diabète de type 2 et selon le stade de l’atteinte rénale :
- Les caractéristiques démographiques et cliniques des patients.
- Les traitements médicamenteux.
- L'incidence des complications rénales et cardiovasculaires.
- L'utilisation et les coûts des soins de santé.
- Patients must fulfill the following criteria to be included in the EMR T2DM sample: -- Adults of 30 years of age and more in the EMR -- AND identification of T2DM in the EMR by: --- At least one GP consultation with a diagnosis of T2DM recorded in the EMR --- AND/OR at least 3 prescriptions (at different dates) of a T2DM marker treatment (oral antidiabetic agents, OAD or GLP-1a); and in case of large conditioning with at least 2 prescriptions during the study period - Patients must fulfill the following criteria to be included in the SNDS T2DM sample: -- Adults over 30 years of age and more in the SNDS -- AND covered by the general health insurance plan in the SNDS -- AND identification of T2DM in the SNDS by: --- Patient receiving oral anti-diabetic treatment: at least 3 deliveries (at different dates) of oral antidiabetic agents (or at least 2 if at least 1 large conditioning) during one year --- AND/OR patient having active long term disease (ALD) in year n with a diagnosis code of T2DM --- AND/OR patient having at least one hospital stay for which the principal diagnosis (DP) or related diagnosis (DR) indicates T2DM --- AND/OR patient having at least one hospital stay for which the DP or DR indicates a complication of T2DM, and T2DM is identified as an associated diagnosis (DA) or as a DP / DR of a medical unit summary (RUM)
- Adults under 30 years of age - Less than 1 year of history in SNDS prior to index date - The beneficiaries who are insufficiently identifiable or who have a technical constraint of the SNDS (pseudonymous, pseudo NIRs, twins, ...) - Patients affiliated to a Mayotte settlement institution (an oversea French department [(250 000 inhabitants/67 million in France]) as some variables such as long-term/chronic disease or death are poorly documented
Locations | Status | |
---|---|---|
Locations Many Locations Many Locations, France | Status Active, not recruiting | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
OREOT – Observational Retrospective pharmaco-Epidemiological French study On CKD in T2DM disease
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1